{{Rsnum
|rsid=829417
|Gene=RAP1GAP
|Chromosome=1
|position=21616643
|Orientation=plus
|GMAF=0.2975
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=RAP1GAP
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 46.9 | 41.6 | 11.5
| HCB | 51.1 | 40.9 | 8.0
| JPT | 76.1 | 22.1 | 1.8
| YRI | 53.1 | 42.9 | 4.1
| ASW | 54.4 | 35.1 | 10.5
| CHB | 51.1 | 40.9 | 8.0
| CHD | 60.6 | 33.9 | 5.5
| GIH | 47.5 | 38.6 | 13.9
| LWK | 62.7 | 31.8 | 5.5
| MEX | 20.7 | 53.4 | 25.9
| MKK | 76.3 | 22.4 | 1.3
| TSI | 52.0 | 42.2 | 5.9
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs829417
|Name_s=
|Gene_s=RAP1GAP
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 176. Study population/ethnicity: 87 European descent Caucasians and 89 Yorubans. Significance metric(s): p = 0.00009. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109453
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs829417
|overall_frequency_n=42
|overall_frequency_d=128
|overall_frequency=0.328125
|n_genomes=28
|n_genomes_annotated=0
|n_haplomes=34
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}
{{on chip | NatGeo2}}